EARNING RECAP

Celgene Corp.

#CELG 2018 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q3 adjusted $2.29 est. $2.22 $3.89B est. $3.85B -2.66% ($72.72 closing) $76.69 $72.30 raises Fy18 adj. EPS & Revenue view: $8.75-$8.80 from $8.70-$8.75 consensus $8.76; $15.2B-$15B consensus $15.17B
Q2 Adjusted EPS $2.16 vs $2.11 $3.81B vs $3.7B +0.73% ($88.31 closing) $89.25 $85.30 Raises FY18 adjusted EPS view to $8.70-$8.75
Q1 adjusted $2.05 est. $1.96 $3.54B est. $3.46B +1.74% ($86.89 closing) $88.88 $85.57 cuts FY18 EPS view to $8.45 from $8.70-$8.90 est. $8.46; FY18 revenue at high end $14.4B-$14.8B est. $14.81B
#CELG 2017 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 adj EPS $2.00 vs $1.97 $3.48B vs $3.47B +1.24% ($104.39 closing) $106.28 $101.80 Sees FY18 adjusted EPS $8.70-8.90 vs $8.64 est.
Q3 adjusted $1.91 vs $1.87 $3.29B vs $3.42B -16.37% ($99.99 closing) $101.15 $94.55 Sees FY17 adjusted EPS $7.30-7.35 Vs $7.31
Q2 $1.85 vs. $1.78 $3.26B vs. $3.23B -2.61% ($134.15 closing) $139 $133 Raises FY17 adjusted EPS $7.25 - $7.35
Q1 $1.68 VS. $1.64 $2.96Bil vs.$3.04Bil -.98% $124.98 $123.97

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.